Taconic Biosciences and Pharmatest Services Ltd. Create First Human Immune System Model for Bone Metastasis
5.7.2017 23:26 | NASDAQ OMX
Researchers hopeful this new model will address incurable and painful disease
Bone metastasis develops when cancer spreads from elsewhere in the body and is a frequent downstream consequence of common cancers, such as breast, prostate, and lung cancer1,2. Human Immune System (HIS) engrafted models are a key research tool for studying immune system effects on disease states and are rapidly becoming the preferred method for testing the efficacy of immune-cell-activating oncology therapeutics. Without a consistent model of responsive human immune cells, it has been difficult to assess human-specific, immune-activating therapies. Taconic's collaboration with Pharmatest brings to the commercial market the first HIS model used for studying bone metastasis.
"Despite its high frequency in breast, prostate, and lung cancer patients, bone metastasis is typically considered to be incurable and therapeutic development for this painful disease has been stymied by the lack of relevant animal models for studying efficacy of immunotherapies. Taconic is excited to partner with Pharmatest to address this large unmet need," shared Dr. Azusa Tanaka, product manager for Taconic's precision research model portfolio.
Pharmatest developed this animal model to clarify the role of human immune cells in bone metastases using Taconic's huNOG model. This model has both human cancer and immune cells in the bone, enabling study of a wide variety of cancer drugs on bone metastasis, including immuno-oncology drugs like checkpoint inhibitors PD-1, PDL-1, and CTLA-4. It is also valuable when human T cells are required for the cancer drug to be efficacious. The model is available via Pharmatest.
"Working with Taconic has been a great pleasure for Pharmatest. We are impressed with the high quality services, top-level scientific support, and fast and clear communication. By using humanized mice provided by Taconic, we have been able to establish more predictive animal models to support immuno-oncology therapy development," stated Dr. Jenni Bernoulli, chief operating officer at Pharmatest.
Taconic offers a full suite of immunology products and services, including germ-free animal models and microbiome services, a portfolio of humanized models based on the severely immune-deficient CIEA NOG mouse®, key inbred strains such as B6, BALB/c, C3H and DBA/1, models on the B6 or BALB/c background which are lacking particular immune cell types or which carry markers such as OT-II, the broadest range of immunodeficient strains for use as xenograft hosts, and a full suite of genomic engineering technologies.
Pharmatest is a preclinical contract research organization that offers high quality efficacy services in oncology and skeletal diseases, such as osteoporosis and osteoarthritis. As bone specialists, Pharmatest also offers bone safety studies and in oncology, Pharmatest has special expertise in clinically predictive orthotopic and metastasis models, and has been the leading global provider of bone metastasis models since 2007. Information can we requested via firstname.lastname@example.org.
To learn more about Taconic's immune-oncology models and services, please call 1-888-TACONIC (888-822-6642) in the US, or +45 70 23 04 05 in Europe, or email email@example.com.
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Kelly Owen Grover
Director of Marketing Communications
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
ATTO ThunderLink® enables VMware® ESXi(TM) for Mac Pro®24.8.2017 10:00 | Pressmeddelande
AMHERST, N.Y., Aug. 24, 2017 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for nearly 30 years, today is proud to announce their 16Gb and 8Gb Fibre Channel ThunderLink® Thunderbolt(TM) devices have achieved VMware Ready(TM) status for ESXi(TM). ATTO ThunderLink devices are the only purpose built Thunderbolt product designed to connect virtualized Mac hardware to 16Gb and 8Gb Fibre Channel storage solutions within VMware® VSphere environments. This provides a new and efficient solution for Apple technologies application development and testing environments, virtual desktop infrastructure and cloud hosting or shared private cloud. "By utilizing an ATTO ThunderLink in a VMware environment users can now take advantage of a one of a kind solution to bring virtualized Macs into test and development environments," said Tom Kolniak, Senior Director of
Karolinska Development - Delårsrapport för januari - juni 2017, inbjudan till telefonkonferens och webbpresentation24.8.2017 08:00 | Pressmeddelande
STOCKHOLM den 24 augusti 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) kommer att offentliggöra delårsrapporten för januari - juni 2017 efter att marknaden har stängt den 29 augusti 2017. Bolaget kommer även att hålla en telefonkonferens och webbpresentation den 30 augusti klockan 14.00 CEST. Vänligen ring in på något av följande telefonnummer några minuter före telefonkonferensens start: Från Sverige: +46 (0) 8 505 564 74 Från USA: +1 855 753 22 30 Från Storbritannien: +44 (0) 20 336 453 74 Webbpresentationen kan samtidigt nås från: https://edge.media-server.com/m6/p/7zkrjqvs Presentatör: Viktor Drvota, VD. För ytterligare information, vänligen kontakta : Viktor Drvota, VD, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karoli
Karolinska Development - Interim Report (January-June 2017) - Invitation to conference call and webcast24.8.2017 08:00 | Pressmeddelande
STOCKHOLM - August 24, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) will publish its Interim Report - January-June 2017 on August 29, 2017 after market closure. The company will also host a conference call and an online presentation on August 30, at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call: The Company will host a conference call on August 30, 2017 at 2 pm CEST. Please dial in at one of the following numbers a few minutes before the start of the conference call: From Sweden: +46 (0) 8 505 564 74 From the US: +1 855 753 22 30 From the UK: +44 (0) 20 336 453 74 The presentation will also be webcast and can be accessed from the following web address: https://edge.media-server.com/m6/p/7zkrjqvs Host: Viktor Drvota, CEO. For further information, please contact: Viktor Drvota, CEO, Karolinska Dev
PayByPhone Appoints Francis Dupuis as new CEO24.8.2017 01:14 | Pressmeddelande
VANCOUVER, British Columbia, Aug. 23, 2017 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it has appointed Francis Dupuis as President and Chief Executive Officer effective August 23rd, 2017. Kush Parikh, former President and CEO, has stepped down from the role after his successful 3.5-year term with the business. During his time at PayByPhone, Kush led the business to profitability, established a strong focus on end customers and was pivotal in its ground-breaking sale to Volkswagen Financial Services. "With more than 20 years of experience in the software industry and a deep product background, Francis is exactly the kind of leader we need to further grow and innovate in the parking market on an international scale," said Stefan Imme, Head of M&A and Investment Management at Volkswagen Financial Services AG. Francis, a long-standing member of the executive team at PayByPhone, takes the reins at a
Kommuniké från extra bolagsstämma i LeoVegas, 23 augusti 201723.8.2017 16:34 | Pressmeddelande
Extra bolagsstämma i LeoVegas AB (publ) ("LeoVegas" eller "Bolaget") hölls idag den 23 augusti 2017 varvid aktieägarna fattade följande beslut. Beslut om incitamentsprogram till anställda Stämman beslutade enhälligt, i enlighet med styrelsens förslag, att emittera högst 1 000 000 teckningsoptioner med avvikelse från aktieägarnas företrädesrätt till följd varav Bolagets aktiekapital kan komma att öka med högst 12 000,000022 euro. Teckningsoptionerna medför rätt till nyteckning av aktier i Bolaget. Incitamentsprogrammet ersätter det från årsstämman den 17 maj 2017 beslutade programmet i vilket samtliga teckningsoptioner makulerats efter beslut av styrelsen den 23 juli 2017 som registrerades hos Bolagsverket den 26 juli 2017. Rätt att teckna teckningsoptionerna ska tillkomma Gears of Leo AB ("Dotterbolaget") med rätt och skyldighet att, vid ett eller flera tillfäl
Announcement from LeoVegas's extra general meeting, 23 August 201723.8.2017 16:34 | Pressmeddelande
The extra general meeting ("EGM") of LeoVegas AB (publ) ("LeoVegas" or the "Company") was held today on 23 August 2017 and the following resolutions were passed. Resolution regarding incentive program for employees The EGM resolved unanimously, in accordance with the board of directors' proposal to issue a maximum of 1,000,000 warrants, with deviation from the shareholders preferential rights, which may result in a maximum increase in the Company's share capital of EUR 12,000.000022. The warrants shall entitle to subscription of new shares in the Company. The incentive program replaces the program resolved on by the annual general meeting held on 17 May 2017 in which all issued warrants have been cancelled in accordance with the board of directors resolution on 23 July 2017 which was registered with the Swedish Companies registration Office on 26 July 2017. The
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum